CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 7 enrolled
Drug / intervention
[14C]IDV184001ANdrug
Likely dose
[14C]IDV184001AN 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05974046
NCT05974046Phase 1Completed
CompareCT.gov

A Phase I, Open Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Dose of Oral [14C]-IDV184001AN in Healthy Adult Male Participants

Indivior Inc.·interventional·Posted Aug 3, 2023·Updated Feb 13, 2025

In Brief

A Phase 1 clinical trial evaluating [14C]IDV184001AN for Opioid Use Disorder. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of \[14C\]-IDV184001AN (\[14C\]-IDV184001) in healthy adult male participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedAug 3, 2023
Enrollment StartJul 10, 2023
Primary CompletionJul 21, 2023
TodayJul 2, 2026
Enrollment to primary: 11 daysPosted 2.9 years ago

Interventions

[14C]IDV184001ANdrug

\[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension